Submission rules before mandatory use: There is no change to the existing submission rules for submissions to NCAs Submission to PSUR Repository is recommended.

Slides:

Advertisements

Similar presentations

Data transfer to the EHES RC Luxembourg

Advertisements

1 Future strategy for e-submission as seen by industry Dr Michael Colmorgen, IFAH-Europe 2nd Veterinary Workshop on E-submission 4 Dec 2009, EMEA, London.

1 Harmonisation of requirements: where we are Erik Waterdrinker, IFAH-Europe 2nd Veterinary Workshop on E-submission 4 Dec 2009, EMEA, London.

22nd May 2007 EURS Implementation Group Terms of Reference and Roadmap.

22nd May 2007 EURS Implementation Group Introduction and Objectives.

Registration in Europe Current situation and future outlook Thomas K ü rner, M.D. Nippon Boehringer Ingelheim Co., Ltd.

Coursework.  5 groups of 4-5 students  2 project options  Full project specifications on 3 rd March  Final deadline 10 th May 2011  Code storage.

Disclaimer The presentation is intended for educational purposes only and does not replace independent professional judgement. Statements of fact and opinions.

CMD(h) Report Progress report Truus Janse-de Hoog HMA meeting Budapest April 2011.

APPLICATION SUBMISSION MADE EASY. How it all Started One of the largest life insurance companies in the country asked CRL if we could provide an easy.

The Gateway What is the Gateway? Gateway Options

16 April 2017 Presenters from EMA

ICT TOOLS AND SOCIETY INVOLVEMENT AMONG THE EUPAN NETWORK HIGHLIGHTS FROM THE SURVEY RESULTS TANYA CHETCUTI EUROPEAN COMMISSION.

Your global support in Europe Over 20 years of experience ELM Pharmaceutica.

Organisation of sampling programmes EU experience Jean-Marc Spieser / Marta Miquel Interregional Seminar for Quality Control Laboratories involved in WHO.

Reconstruction of the Pharmacovigilance System

EFPIA EFPIA IT Proposals ppt Slide 1 EFPIA Proposals for IT Support to the European Regulatory Procedures Mr S. Hasler EFPIA PAT Regulation 2000.

EMACOLEX, May 2011 Recent activities of the HMA/EMA Transparency Group Tina Engraff Legal Adviser, Danish Medicines Agency.

An agency of the European Union Presented by: David Mackay Head of Unit, Veterinary Medicines & Product Data Management Unit Incident Management Plan Veterinary.

International Atomic Energy Agency 1 Opening free access to the INIS DB and NCL Part 1 The 34 th Consultative Meeting of INIS Liaison Officers Vienna,

European Enforcement of Pharmacovigilance and Inspection Trends Is compliance possible within the EU? June 7, 2007 Dr. M.C. Koster CEO Vigilex Group.

An agency of the European Union Presented by: Emer Cooke and Truus Janse-de Hoog Update on Transparency Progress report from HMA/EMA TF on Transparency.

Paediatric Worksharing CMDh participation Work-sharing in Art 45 and 46 procedures Experiences in Art 29 procedures Presidency meeting 29 September 2011.

Best Archival Practice in the Regulation of Medicines: Work on the Guidelines for Agencies for Medicinal Products Ph.D. Arian Rajh Agency for Medicinal.

Training Session Product File Notes and Registration Reports, 23 October Welcome ! Federal Public Service of Public Health, Food Chain Safety and.

Agenda Overview and Status of Implementation Speaker: Georg Neuwirther (AGES, chair eAF MG) Processing the eAF for initial application Speaker: Kristiina.

CTD Dossier Preparation K. Srikantha Reddy Sr

LG DATABASE AND REPORTING SYSTEM (LGDRS) 8-9 September 2015

U.S. Environmental Protection Agency Central Data Exchange Pilot Project Promoting Geospatial Data Exchange Between EPA and State Partners. April 25, 2007.

Results of IFAH Survey on readiness of Industry for e- Submissions 7 May 2009.

Analysis following the update of the GSE Investment Database February 2010.

Federal agency for medicines and health products VARIATIONS AND HOMEOPATHIC MEDICINAL PRODUCTS Marie-Anne Mouyart – Belgium, Unit Homeo-Phyto HMPWG Gdańsk.

Academic Information Portal PIA

1. 2 > ˜100 3 >2 000 > Paediatric regulation.

European Patients’ Academy on Therapeutic Innovation Marketing authorisation.

European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Periodic Safety Update Reports (PSURs)

Overview of the EU regulatory system and governance

China EU Pharmaceutical Forum

Swissmedic Swiss Agency for Therapeutic Products Hallerstrasse 7 CH-3000 Bern From Step 2 to Step 3 of the eCTD Introduction 2nd Follow-up.

1 Division of Pharmacoepidemiology and Pharmacovigilance AEMPS Dolores Montero Corominas 20 November Management of the Adverse drug reaction (ADR),

Roles, responsabilities and outcomes of conduction pharmacovigilance inspections in EU Directorate of Risk Management of Medicines National Authority of.

Swissmedic Schweizerisches Heilmittelinstitut Hallerstrasse 7 CH-3000 Bern PSUR und E2E/RMP-Updates 2nd Follow-up Information Meeting.

#SummitNow Dynamic Data List Driven Constraints in Share November 14 th, 2013 Tony Parzgnat – Technology Services Group.

PHC Meeting the global challenge of unique identification of medicinal products SMS, RMS and OMS : Common Terminologies for enabling ISO IDMP.

Statement of Intent Background CESSP Phase 1 - implementation

Paediatric Medicine: The Paediatric Investigation Plan

Free open access. No registration or log-in required

Periodic Safety Update Reports (PSUR)

LITERATURE REVIEW As the pharmaceutical industries throughout the world are moving ahead towards becoming more and more competitive, regulatory agencies.

EudraVigilance.

Multinational collaboration in the Authorisation of VMPs: the EU approach VICH Outreach Forum Tokyo, Nov 2017 Noel Joseph European Commission.

Guideline prepared by the Veterinary Harmonisation Group

eSubmission Web Client – XML delivery files

TAIEX, Istanbul, April 19th, 2011

eSubmission PSUR XML Delivery File

Updated eSubmission Roadmap (v.2.1) Adopted by HMA on

Vytenis Andriukaitis European Commissioner for Health and Food Safety

CESSP Phase 1 Essential project information.

Helen Lee, European Commission

eSubmission Web Client XML delivery file – new functionality

EU SUBMISSION BY Haripriya & Revathy.

Viewing and updating (meta)data Deleting sites

CESSP Phase 1 Essential project information.

Business Cases and Advantages of eCTD v4.0

IT tool training Biocides Day 25th of October :30-11:15 IUCLID

Business View on eCTD v4.0 Advantages and challenges when considering implementation to overcome constrains of the current eCTD specification.

EVDAS en EVWEB: raak er niet in verstrikt

Pharmacovigilance updates

1st meeting of the CIOMS Working Group XI, 19 April 2018

Updated eSubmission Roadmap (v2.2) Adopted by HMA on 21 June 2019

Presentation transcript:

Submission rules before mandatory use: There is no change to the existing submission rules for submissions to NCAs Submission to PSUR Repository is recommended for all PSURs (also non pilot products/supplementary information) CAPs: To the European Medicines Agency – submission through eSubmission Gateway/ Web Client including XML delivery file created in the PSUR Repository user interfacePSUR Repository user interface Follow CAP Dossier Requirements document for NCA submissions for countries not yet using the Common RepositoryCAP Dossier Requirements

Submission rules: NAPs: Mixed CAP/NAP PSUSA procedure: To all Member States in which the medicinal product has been authorised - (refer to Requirements for submissions for Periodic Safety Update Reports (PSUR) for MRP, DCP and National Products (NAPs))Requirements for submissions for Periodic Safety Update Reports (PSUR) for MRP, DCP and National Products (NAPs) To the PRAC Rapporteur (refer to Requirements for submissions for Periodic Safety Update Reports (PSUR) for MRP, DCP and National Products (NAPs)Requirements for submissions for Periodic Safety Update Reports (PSUR) for MRP, DCP and National Products (NAPs) To the European Medicines Agency – submission through eSubmission Gateway/ Web Client including XML delivery file created in the PSUR Repository user interface.PSUR Repository user interface

Submission rules: NAPs: NAP/NAP PSUSA procedure: To all Member States in which the medicinal product has been authorised - (refer to Requirements for submissions for Periodic Safety Update Reports (PSUR) for MRP, DCP and National Products (NAPs))Requirements for submissions for Periodic Safety Update Reports (PSUR) for MRP, DCP and National Products (NAPs) Lead Member State appointed for the procedure (even if the product is not authorised in that Member State) (refer to Requirements for submissions for Periodic Safety Update Reports (PSUR) for MRP, DCP and National Products (NAPs))Requirements for submissions for Periodic Safety Update Reports (PSUR) for MRP, DCP and National Products (NAPs) To the European Medicines Agency – submission through eSubmission Gateway/ Web Client including XML delivery file created in the PSUR Repository user interface.PSUR Repository user interface